Literature DB >> 15712344

PIK3CA mutations in advanced ovarian carcinomas.

Yun Wang1, Aslaug Helland, Ruth Holm, Gunnar B Kristensen, Anne-Lise Børresen-Dale.   

Abstract

PIK3CA belongs to the phosphatidylinositol 3-kinases (PI3Ks) family, which play an important role in proliferation, adherence, transformation and cell survival through the PI3K/AKT signaling pathway. Somatic activating mutations of this gene have recently been detected in several types of cancers. In the present study, 109 advanced ovarian carcinomas were analyzed for PIK3CA mutations in exon 9 and exon 20 by direct sequencing. Activating missense mutations were observed in 4 of the 109 tumors in addition to one variant leading no change of the PIK3CA protein. Two of the cases with mutations were mucinous and clear cell tumors, suggesting that PIK3CA mutations are more common in these rare histological types. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15712344     DOI: 10.1002/humu.9316

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  38 in total

Review 1.  Oncogenic mutations of PIK3CA in human cancers.

Authors:  Yardena Samuels; Todd Waldman
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

2.  Cancer-specific mutations in PIK3CA are oncogenic in vivo.

Authors:  Andreas G Bader; Sohye Kang; Peter K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

Review 3.  Class I PI3K in oncogenic cellular transformation.

Authors:  L Zhao; P K Vogt
Journal:  Oncogene       Date:  2008-09-18       Impact factor: 9.867

4.  High-throughput mutation profiling in intraductal papillary mucinous neoplasm (IPMN).

Authors:  Nir Lubezky; Menahem Ben-Haim; Sylvia Marmor; Eli Brazowsky; Gideon Rechavi; Joseph M Klausner; Yoram Cohen
Journal:  J Gastrointest Surg       Date:  2011-01-12       Impact factor: 3.452

5.  Type I to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer.

Authors:  Rong Wu; Suzanne J Baker; Tom C Hu; Kyle M Norman; Eric R Fearon; Kathleen R Cho
Journal:  Am J Pathol       Date:  2013-04       Impact factor: 4.307

6.  The role of activin A and Akt/GSK signaling in ovarian tumor biology.

Authors:  Thuy-Vy Do; Lena A Kubba; Monica Antenos; Alfred W Rademaker; Charles D Sturgis; Teresa K Woodruff
Journal:  Endocrinology       Date:  2008-05-01       Impact factor: 4.736

7.  PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas.

Authors:  Frank Schönleben; Wanglong Qiu; Helen E Remotti; Werner Hohenberger; Gloria H Su
Journal:  Langenbecks Arch Surg       Date:  2008-02-21       Impact factor: 3.445

8.  PIK3CA mutations in head and neck squamous cell carcinoma.

Authors:  Wanglong Qiu; Frank Schönleben; Xiaojun Li; Daniel J Ho; Lanny G Close; Spiros Manolidis; Boyce P Bennett; Gloria H Su
Journal:  Clin Cancer Res       Date:  2006-03-01       Impact factor: 12.531

9.  PIK3CA alterations in Middle Eastern ovarian cancers.

Authors:  Jehad Abubaker; Prashant Bavi; Wael Al-Haqawi; Zeenath Jehan; Adnan Munkarah; Shahab Uddin; Khawla S Al-Kuraya
Journal:  Mol Cancer       Date:  2009-07-28       Impact factor: 27.401

10.  Expression of activated PIK3CA in ovarian surface epithelium results in hyperplasia but not tumor formation.

Authors:  Shun Liang; Nuo Yang; Yue Pan; Shan Deng; Xiaojuan Lin; Xiaojun Yang; Dionyssios Katsaros; Katherine F Roby; Thomas C Hamilton; Denise C Connolly; George Coukos; Lin Zhang
Journal:  PLoS One       Date:  2009-01-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.